Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

BACKGROUND: In melanoma patients who progress after prior ipilimumab/nivolumab (ipi/nivo) combination immunotherapy, there is no information regarding the risks and benefits of reinduction ipi/nivo. METHODS: This was a retrospective review of 26 melanoma patients treated at Memorial Sloan Kettering...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Paul B, Jayaprakasam, Vetri Sudar, Panageas, Katherine S, Callahan, Margaret, Postow, Michael A, Shoushtari, Alexander N, Wolchok, Jedd D, Betof Warner, Allison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549669/
https://www.ncbi.nlm.nih.gov/pubmed/34702752
http://dx.doi.org/10.1136/jitc-2021-003395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549669/
https://www.ncbi.nlm.nih.gov/pubmed/34702752
http://dx.doi.org/10.1136/jitc-2021-003395

Ejemplares similares